Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sunshine rules ensnare Emory department chair

Executive Summary

Charles Nemeroff is stepping down as chairman of the Department of Psychiatry and Behavioral Sciences at Emory University School of Medicine because of failure to report outside income from drug companies. An investigation by Emory found that during 2000-2005, Nemeroff failed to report more than $800,000 in income from GSK for more than 250 speaking engagements. Nemeroff says he believed his presentations to be educational lectures not subject to the school's disclosure requirements. The investigation, which focused on the GSK payments because the firm was the largest single payer to Nemeroff, has found no evidence the payments affected his care for clinical trial participants or biased his research. Nevertheless, Nemeroff, who will continue to teach at Emory, will be subject to new restrictions on his outside activities. Sen. Chuck Grassley, R-Iowa, brought attention to Nemeroff's activities as part of his campaign to shed light on drug companies' financial ties to doctors and researchers (1"The Pink Sheet," Sept. 22, 2008, In Brief)

You may also be interested in...



Grassley pushes universities for transparency

Officials at academic research institutions are the latest group to feel pressure from Sen. Chuck Grassley, R-Iowa, who is looking to shed light on drug companies' financial ties to researchers. The ranking Republican on the Senate Finance Committee sent letters to leaders of almost two dozen universities asking them to examine their conflict of interest and financial disclosure policies. Grassley says he is concerned that drug company funding can influence scientific studies and that university faculty do not always report their outside income. Grassley previously prodded NIH director Elias Zerhouni to review his agency's oversight of outside grant recipients' conflicts of interest (1"The Pink Sheet," June 30, 2008, In Brief)

US FDA Connects Dots For Drug Manufacturers’ Responses To CRLs With Draft Guidance

CRLs FDA submits in response to ANDAs increased most years since FY 2015, though FY 2020 total likely will be lower than two previous years. A 2019 CRL interrupted GSK's plans to market first mouth spray nicotine replacement therapy in US.

Inovio COVID-19 Vaccine Trial Delayed By FDA Partial Hold

The US FDA appears to have concerns about the device used to administer the vaccine.

Topics

UsernamePublicRestriction

Register

ID1128360

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel